Related Experiment Video
Updated: May 5, 2026
09:18
Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux
Published on: September 17, 2019
4.4K
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences
Meagan S Barbee1, R Donald Harvey, Sagar Lonial
1Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA.
The Annals of Pharmacotherapy
|November 22, 2013
Summary
Subcutaneous bortezomib offers improved efficiency and patient preference over intravenous administration for multiple myeloma treatment. This method reduces chair time and overall visit duration, enhancing patient satisfaction.
Area of Science:
- Hematology
- Clinical Pharmacy
- Oncology
Background:
- Subcutaneous bortezomib demonstrates comparable efficacy to intravenous administration for multiple myeloma.
- Previous research indicates subcutaneous bortezomib is associated with reduced neuropathy incidence.
- Limited data exists on the impact of subcutaneous bortezomib on practice efficiency and patient preferences.
Purpose of the Study:
- To evaluate and quantify differences in practice efficiency variables between subcutaneous and intravenous bortezomib administration.
- To assess and compare patient preferences and satisfaction levels for subcutaneous versus intravenous bortezomib.
- To analyze the effect of bortezomib administration route on infusion center logistics and patient experience.
Main Methods:
- A two-part study involving retrospective medical record review and patient surveys.
- Efficiency metrics including infusion chair time and total visit duration were analyzed for patients receiving at least six bortezomib doses.
- Patient surveys collected data on preferences, satisfaction, injection site reactions, and quality of life for those receiving both administration routes.
Main Results:
- Subcutaneous bortezomib significantly reduced chair time by 38% and overall visit time by 27% compared to intravenous administration.
- A majority of surveyed patients (68%) preferred subcutaneous bortezomib and reported higher satisfaction.
- Injection site reactions occurred in 39% of patients, with no significant difference between preference groups.
Conclusions:
- Subcutaneous bortezomib administration is more time-efficient for both patients and healthcare institutions.
- Patients demonstrate a clear preference for subcutaneous bortezomib over the intravenous route.
- The findings support the adoption of subcutaneous bortezomib for improved patient experience and operational efficiency in multiple myeloma care.
Related Concept Videos
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
1.1K
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
1.1K
01:25Routes of Drug Administration: Parenteral
3.7K
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
3.7K
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
428
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
428
01:28IV Infusion to Oral Dosing: Conversion Methods
214
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
214
01:18Two-Compartment Open Model: IV Bolus Administration
1.4K
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
The disparity between drug input and the sum of drug transfer rates between...
1.4K
00:56One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
498
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
498